A Phase I, Open Label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Effect of Steady-state TMC278 on the Pharmacokinetics of a Single Dose of Digoxin.

Trial Profile

A Phase I, Open Label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Effect of Steady-state TMC278 on the Pharmacokinetics of a Single Dose of Digoxin.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Rilpivirine (Primary) ; Digoxin
  • Indications Atrial fibrillation; Atrial flutter; Heart failure; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 13 Jul 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2011-004159-38).
    • 29 Jun 2012 Company changed from Tibotec Pharmaceuticals Ireland to Janssen R&D Ireland as reported by ClinicalTrials.gov.
    • 29 Jun 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top